Home Cart Sign in  
Chemical Structure| 75172-81-5 Chemical Structure| 75172-81-5

Structure of Migalastat HCl
CAS No.: 75172-81-5

Chemical Structure| 75172-81-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Migalastat hydrochloride is a potent and selective α-galactosidase inhibitor (α-Gal A) with IC50 of 0.04 μM.

Synonyms: GR181413A; 1-Deoxygalactonojirimycin (hydrochloride); Migalastat

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Migalastat HCl

CAS No. :75172-81-5
Formula : C6H14ClNO4
M.W : 199.63
SMILES Code : O[C@H]1[C@@H](CO)NC[C@H](O)[C@H]1O.[H]Cl
Synonyms :
GR181413A; 1-Deoxygalactonojirimycin (hydrochloride); Migalastat
MDL No. :MFCD00269962

Safety of Migalastat HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03683966 - Recruiting March 31, 2019 Germany ... More >> Wuerzburg University Hospital Recruiting Würzburg, Bayern, Germany, 97080 Contact: Irina Schumacher    004993120139714    schumacher_i@ukw.de Less <<
NCT01730482 Fabry Disease Phase 1 Completed - -
NCT01218659 Fabry Disease Phase 3 Completed - -
NCT01218659 - Completed - -
NCT01489995 Fabry Disease Phase 1 Completed - United States, Texas ... More >> GSK Investigational Site Austin, Texas, United States, 78744 Less <<
NCT00925301 - Completed - -
NCT01730469 Fabry Disease Phase 1 Completed - United States, California ... More >> GSK Investigational Site Costa Mesa, California, United States, 92626 United States, Florida GSK Investigational Site Miami, Florida, United States, 33014 GSK Investigational Site Miami, Florida, United States, 33169 GSK Investigational Site Orlando, Florida, United States, 32809 Less <<
NCT01196871 Fabry Disease Phase 2 Completed - United States, Alabama ... More >> Birmingham, Alabama, United States, 35294 United States, Georgia Decatur, Georgia, United States, 30033 United States, Iowa Iowa City, Iowa, United States, 52242 United States, Kansas Kansas City, Kansas, United States, 66160 United States, Virginia Springfield, Virginia, United States, 22152 Australia Nedlands, Australia Parkville, Australia Belgium Edegem, Belgium Canada Montreal, Canada Netherlands Amsterdam, Netherlands Less <<
NCT00283959 - Completed - -
NCT01196871 - Completed - -
NCT00283933 Fabry Disease Phase 2 Completed - France ... More >> Paris, France, 75015 United Kingdom London, United Kingdom, NW3 2QG Less <<
NCT01853852 Fabry Disease Phase 1 Completed - Australia, New South Wales ... More >> GSK Investigational Site Randwick, New South Wales, Australia, 2031 Less <<
NCT00283933 - Completed - -
NCT00304512 Fabry Disease Phase 2 Completed - United States, Georgia ... More >> Decatur, Georgia, United States, 30033 Australia, Victoria Parkville, Victoria, Australia, 3050 Brazil Porto Alegre, Brazil, RS, 90035-903 Canada Montréal, Canada, H4J 1C5 France Paris, France, 75015 United Kingdom Salford, United Kingdom, M6 8HD Less <<
NCT00304512 - Completed - -
NCT01458119 Fabry Disease Phase 3 Terminated(Amicus Therapeutics... More >> discontinued Study AT1001-041 for logistical reasons.) Less << - -
NCT00283959 Fabry Disease Phase 2 Completed - Australia ... More >> Parkville, Australia Brazil Porto Alegre, Brazil Less <<
NCT01458119 - Terminated(Amicus Therapeutics... More >> discontinued Study AT1001-041 for logistical reasons.) Less << - -
NCT00526071 Fabry Disease Phase 2 Terminated(The Sponsor (Amicus... More >> Therapeutics) terminated this study for logistical reasons.) Less << - United States, Georgia ... More >> Decatur, Georgia, United States, 30033 United States, New York New York, New York, United States, 10016 United States, Texas Dallas, Texas, United States, 78226 Australia Parkville, Australia Brazil Porto Alegre, Brazil France Garches, France United Kingdom London, United Kingdom Salford, United Kingdom Less <<
NCT00214500 Fabry Disease Phase 2 Completed - United States, California ... More >> Los Angeles, California, United States, 90048 United States, Georgia Decatur, Georgia, United States, 30033 United States, Maryland Bethesda, Maryland, United States, 20892 United States, New York New York, New York, United States, 10016 United States, Texas Houston, Texas, United States, 77030 Less <<
NCT03135197 - Active, not recruiting September 2019 Germany ... More >> Universtiy Hospital Münster Münster, Germany, 48149 Less <<
NCT00214500 - Completed - -
NCT01476163 - - - United States, California ... More >> CHOC Children's Hospital Division of Metabolic Disease Orange, California, United States, 92868 Contact: Nina Movsesyan, PhD    714-509-3008    nmovsesyan@CHOC.org    Principal Investigator: Raymond Y Wang, MD          United States, Maryland University of Maryland Medical Center Baltimore, Maryland, United States, 21201 Contact: Elizabeth A Streeten, MD    410-706-6236    estreete@som.umaryland.edu    United States, Massachusetts Kidney Care and Transplant Services of New England Springfield, Massachusetts, United States, 01104 Contact: Gregory L Braden, MD    413-733-0010    Gregory.Braden@baystatehealth.org    Contact: Ann Vasseur    (413) 733-0010 ext 143    ann@kidneycare-ne.com    United States, New York Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 Contact: Manisha Balwani, MD    212-241-0915    manisha.balwani@mssm.edu    Contact: Chanan Stauffer, MS, RN    212-241-0395    chanan.stauffer@mssm.edu    Australia, Victoria Royal Melbourne Hospital Parkville, Victoria, Australia, 3050 Contact: Donna North    +61 03 934 24219    donna.north@mh.org.au    Principal Investigator: Kathleen Nicholls, MD Less <<
NCT02082327 Fabry Disease Phase 1 Completed - Netherlands ... More >> PRA International Groningen, Netherlands, 9713 GZ Less <<
NCT02194985 Fabry Disease Phase 3 Active, not recruiting October 2019 -
NCT03500094 Fabry Disease Phase 3 Recruiting September 1, 2020 United States, Florida ... More >> University of South Florida Recruiting Tampa, Florida, United States, 33606 United States, Georgia Emory University Division of Medical Genetics Recruiting Decatur, Georgia, United States, 30033 United States, Missouri University of Missouri Recruiting Columbia, Missouri, United States, 65201 United States, Ohio Cincinnati Children's Hospital Not yet recruiting Cincinnati, Ohio, United States, 45229 United States, Pennsylvania Children's Hospital of Philadelphia Not yet recruiting Philadelphia, Pennsylvania, United States, 19104 Children's Hospital of Pittsburgh of UPMC Recruiting Pittsburgh, Pennsylvania, United States, 15224 United States, Virginia Lysosomal & Rare Disorders Research & Treatment Center Recruiting Fairfax, Virginia, United States, 22030 Less <<
NCT00925301 Fabry Disease Phase 3 Completed - -
NCT00526071 - Terminated(The Sponsor (Amicus... More >> Therapeutics) terminated this study for logistical reasons.) Less << - -
NCT03949920 Fabry Disease ACTIVE_NOT_RECRUITING 2023-12-31 Manchester University Foundati... More >>on Trust, Manchester, M139LT, United Kingdom|Salford Royal NHS Foundation Trust, Manchester, M6 8HD, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.01mL

1.00mL

0.50mL

25.05mL

5.01mL

2.50mL

50.09mL

10.02mL

5.01mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
 

Historical Records

Categories